These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 30600739)

  • 1. Efficacy and safety of nanoparticle albumin-bound paclitaxel in non-small cell lung cancer: a systematic review and meta-analysis.
    Tan H; Hu J; Liu S
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):268-277. PubMed ID: 30600739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Albumin-Bound Paclitaxel: A Review in Non-Small Cell Lung Cancer.
    Blair HA; Deeks ED
    Drugs; 2015 Nov; 75(17):2017-24. PubMed ID: 26541764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.
    Socinski MA; Bondarenko I; Karaseva NA; Makhson AM; Vynnychenko I; Okamoto I; Hon JK; Hirsh V; Bhar P; Zhang H; Iglesias JL; Renschler MF
    J Clin Oncol; 2012 Jun; 30(17):2055-62. PubMed ID: 22547591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients.
    Bertino EM; Williams TM; Nana-Sinkam SP; Shilo K; Chatterjee M; Mo X; Rahmani M; Phillips GS; Villalona-Calero MA; Otterson GA
    Clin Lung Cancer; 2015 Nov; 16(6):466-74. PubMed ID: 26123189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer.
    Socinski MA; Langer CJ; Okamoto I; Hon JK; Hirsh V; Dakhil SR; Page RD; Orsini J; Zhang H; Renschler MF
    Ann Oncol; 2013 Feb; 24(2):314-321. PubMed ID: 23123509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer.
    Socinski MA; Manikhas GM; Stroyakovsky DL; Makhson AN; Cheporov SV; Orlov SV; Yablonsky PK; Bhar P; Iglesias J
    J Thorac Oncol; 2010 Jun; 5(6):852-61. PubMed ID: 20521351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer.
    Socinski MA; Okamoto I; Hon JK; Hirsh V; Dakhil SR; Page RD; Orsini J; Yamamoto N; Zhang H; Renschler MF
    Ann Oncol; 2013 Sep; 24(9):2390-6. PubMed ID: 23842283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patients.
    Tanaka M; Hattori Y; Ishii T; Tohnai R; Itoh S; Kawa Y; Kono Y; Urata Y; Satouchi M
    Respir Investig; 2020 Jul; 58(4):269-274. PubMed ID: 32111518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial.
    Spigel DR; Jotte RM; Aix SP; Gressot L; Morgensztern D; McCleod M; Socinski MA; Daniel D; Juan-Vidal O; Mileham KF; West H; Page R; Reinmuth N; Knoble J; Chen T; Bhore R; Wolfsteiner M; Ong TJ; Gridelli C; Thomas M;
    Clin Lung Cancer; 2021 Jan; 22(1):6-15.e4. PubMed ID: 33097414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Evidence of Safety and Efficacy of Carboplatin plus Nanoparticle Albumin-Bound Paclitaxel in Patients with Advanced Non-Small-Cell Lung Cancer and Preexisting Interstitial Lung Disease: A Retrospective Study.
    Araya T; Kita T; Ueda T; Terada N; Sakai T; Yamamura K; Kurokawa K; Uchida Y; Sone T; Kimura H; Kasahara K
    Can Respir J; 2019; 2019():5315903. PubMed ID: 31015884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Diabetes.
    Hirsh V; Ko A; Pilot R; Renschler MF; Socinski MA
    Clin Lung Cancer; 2016 Sep; 17(5):367-374. PubMed ID: 27230605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer.
    Satouchi M; Okamoto I; Sakai H; Yamamoto N; Ichinose Y; Ohmatsu H; Nogami N; Takeda K; Mitsudomi T; Kasahara K; Negoro S
    Lung Cancer; 2013 Jul; 81(1):97-101. PubMed ID: 23545279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carboplatin plus weekly nanoparticle albumin-bound paclitaxel in elderly patients with previously untreated advanced squamous non-small-cell lung cancer selected based on Mini Nutritional Assessment short-form scores: a multicenter phase 2 study.
    Shiroyama T; Tamiya M; Minami S; Takata S; Masuhiro K; Futami-Nishijima Y; Uenami T; Mori M; Koba T; Matsuki T; Takimoto T; Suzuki H; Okamoto N; Komuta K; Hirashima T; Kumanogoh A; Kijima T
    Cancer Chemother Pharmacol; 2017 Sep; 80(3):461-467. PubMed ID: 28688052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC).
    Morgensztern D; Cobo M; Ponce Aix S; Postmus PE; Lewanski CR; Bennouna J; Fischer JR; Juan-Vidal O; Stewart DJ; Fasola G; Ardizzoni A; Bhore R; Wolfsteiner M; Talbot DC; Jin Ong T; Govindan R; On Behalf Of The Abound L Investigators
    Cancer; 2018 Dec; 124(24):4667-4675. PubMed ID: 30383906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-reported neuropathy and taxane-associated symptoms in a phase 3 trial of nab-paclitaxel plus carboplatin versus solvent-based paclitaxel plus carboplatin for advanced non-small-cell lung cancer.
    Hirsh V; Okamoto I; Hon JK; Page RD; Orsini J; Sakai H; Zhang H; Renschler MF; Socinski MA
    J Thorac Oncol; 2014 Jan; 9(1):83-90. PubMed ID: 24346096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301.
    Miyauchi E; Inoue A; Usui K; Sugawara S; Maemondo M; Saito H; Fujita Y; Kato T; Suzuki T; Harada T; Watanabe H; Nakagawa T; Ichinose M
    Oncologist; 2017 Jun; 22(6):640-e59. PubMed ID: 28526722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Effectiveness and Resource Usage in Patients Receiving First-line Taxane-based Chemotherapy for Stage IV Non-Small-cell Lung Cancer in a US Community Oncology Setting.
    Weiss J; Force RW; Pugmire BA; Peterson T; Faria C; Margunato-Debay S; Patel MB
    Clin Lung Cancer; 2017 Jul; 18(4):372-380.e1. PubMed ID: 28117221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Safety and Efficacy of Treatment with Nab-paclitaxel and Carboplatin for Patients with Advanced Squamous Non-small Cell Lung Cancer Concurrent with Idiopathic Interstitial Pneumonias.
    Fujita T; Hiroishi T; Shikano K; Yanagisawa A; Hayama N; Amano H; Nakamura M; Hirano S; Tabeta H; Nakamura S
    Intern Med; 2018 Jul; 57(13):1827-1832. PubMed ID: 29434143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel.
    Langer CJ; Hirsh V; Okamoto I; Lin FJ; Wan Y; Whiting S; Ong TJ; Renschler MF; Botteman MF
    Br J Cancer; 2015 Jun; 113(1):20-9. PubMed ID: 26035702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: analysis of safety and efficacy in patients with renal impairment.
    Langer CJ; Hirsh V; Ko A; Renschler MF; Socinski MA
    Clin Lung Cancer; 2015 Mar; 16(2):112-20. PubMed ID: 25572008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.